Analyst Tracker/Stephen Baxter

Stephen Baxter

Q: How accurate are Stephen Baxter's stock ratings?

About 57% of Stephen's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, measured by 13Foresight from historical prices.

Q: How is Stephen ranked?

Stephen Baxter is ranked #462 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Wells Fargo

Wall Street Analyst

★★★★☆

#462

on 13Foresight · ranked by our own returns

57%

Success Rate

+5.8%

Average Return

54 of 94 calls profitable · +2.4% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 57% of Stephen Baxter's ratings turned a profit when each position was held for 1 year — averaging +5.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

96 Buy 65 Hold 11 Sell

Stephen's Stock Coverage 28 ratings · 2026-09-22

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
OSCR Oscar Health	Sep 16, 2026	HOLD	Buy -15.3% avg upside 16 analysts	$27.00 13.62% Downside	-0.7%	·
ELV Elevance Health	Sep 15, 2026	BUY	Strong Buy +10.3% avg upside 33 analysts	$473.00 15.63% Upside	-2.0%	·
MOH Molina Healthcare	Sep 15, 2026	HOLD	Buy +18.8% avg upside 26 analysts	$220.00 11.20% Upside	-4.4%	·
HUM Humana	Sep 15, 2026	BUY	Buy +9.8% avg upside 34 analysts	$502.00 32.55% Upside	-2.6%	·
CVS CVS Health	Sep 15, 2026	BUY	Strong Buy +22.4% avg upside 39 analysts	$123.00 40.45% Upside	-6.0%	·
CI Cigna	Sep 15, 2026	HOLD	Strong Buy +25.2% avg upside 30 analysts	$307.00 11.92% Upside	-4.7%	·
CNC Centene	Sep 15, 2026	HOLD	Buy +10.6% avg upside 29 analysts	$69.00 6.20% Upside	-6.4%	·
UNH UnitedHealth	Sep 15, 2026	BUY	Strong Buy +21.3% avg upside 36 analysts	$526.00 39.31% Upside	+0.3%	·
CAH Cardinal Health	Sep 09, 2026	BUY	Strong Buy -6.3% avg upside 30 analysts	$277.00 22.76% Upside	-5.9%	·
UHS Universal Health	Sep 08, 2026	HOLD	Buy +9.7% avg upside 22 analysts	$166.00 4.99% Downside	+2.6%	·
LMRI Lumexa Imaging Holdings, Inc.	Aug 14, 2026	BUY	Strong Buy +78.7% avg upside 8 analysts	$19.00 77.81% Upside	-7.8%	·
COR Cencora	Aug 11, 2026	BUY	Buy +2.7% avg upside 45 analysts	$395.00 24.78% Upside	-5.0%	·
MCK McKesson	Aug 11, 2026	HOLD	Strong Buy -12.9% avg upside 29 analysts	$933.00 5.20% Upside	-1.6%	·
CON Concentra Group Holdings Parent, Inc.	Aug 11, 2026	BUY	Strong Buy +13.4% avg upside 12 analysts	$40.00 15.11% Upside	+7.8%	·
MDLN Medline	Aug 11, 2026	HOLD	Strong Buy +46.0% avg upside 27 analysts	$34.00 6.30% Upside	-8.8%	·
PNTG Pennant Group	Aug 10, 2026	BUY	Strong Buy -5.6% avg upside 9 analysts	$46.00 18.14% Upside	-0.1%	·
AGL Agilon Health	Aug 10, 2026	BUY	Buy -21.1% avg upside 26 analysts	$146.00 65.94% Upside	-7.9%	·
BTSG BrightSpring Health Services, Inc.	Aug 03, 2026	BUY	Strong Buy +16.9% avg upside 20 analysts	$78.00 39.55% Upside	-6.1%	·
HCA HCA Healthcare	Aug 03, 2026	HOLD	Buy -5.5% avg upside 36 analysts	$381.00 10.58% Downside	+5.0%	·
THC Tenet Healthcare	Jul 31, 2026	BUY	Strong Buy -8.2% avg upside 27 analysts	$281.00 7.66% Upside	+2.4%	·
CYH Community Health	Apr 27, 2026	SELL	Sell +43.8% avg upside 18 analysts	$2.00 30.89% Downside	-2.9%	·
TDOC Teladoc	Oct 29, 2025	HOLD	Buy +361.7% avg upside 38 analysts	$8.00 27.60% Upside	-23.4%	·
AMWL American Well	May 01, 2024	HOLD	Hold +19.6% avg upside 15 analysts	$40.00 198.13% Upside	-41.7%	·
LH Labcorp Holdings	Jan 11, 2021	HOLD	Strong Buy -15.7% avg upside 37 analysts	$235.00 26.86% Downside	+34.5%	·
MEDP Medpace Holdings	May 13, 2020	HOLD	Hold -22.6% avg upside 17 analysts	$91.00 85.48% Downside	+99.7%	·
DGX Quest Diagnostics	Apr 27, 2020	HOLD	Buy -25.1% avg upside 34 analysts	$116.00 52.69% Downside	+16.2%	·
CRL Charles River Labs	Feb 18, 2020	BUY	Strong Buy -13.6% avg upside 35 analysts	$203.00 27.15% Downside	+66.3%	·
IQV IQVIA Holdings	Nov 14, 2019	BUY	Strong Buy -8.3% avg upside 39 analysts	—	+19.4%	·

🔒 23 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Stephen Baxter — Frequently Asked Questions

How accurate are Stephen Baxter's stock ratings?

Based on the calls 13Foresight could measure, about 57% of Stephen's ratings were profitable over a one-year hold, with an average return of +5.8% per rating, or +2.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Stephen ranked on 13Foresight?

Stephen Baxter is currently ranked #462 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Stephen cover?

Stephen most recently has ratings on OSCR, ELV, MOH, HUM, CVS, CI, CNC, UNH, CAH, UHS, LMRI, COR and 16 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Stephen Baxter

Rating Distribution

Welcome to 13Foresight!